TY  - JOUR
AU  - Gomez-Garcia, Francisco
AU  - Gomez-Arias, Pedro Jesus
AU  - Montilla-Lopez, Ana
AU  - Hernandez-Parada, Jorge
AU  - Sanz-Cabanillas, Juan Luis
AU  - Ruano, Juan
AU  - Parra-Peralbo, Esmeralda
PY  - 2022
DO  - 10.3389/fmed.2022.754116
SN  - 2296-858X
UR  - http://hdl.handle.net/10668/20601
T2  - Frontiers in medicine
AB  - The Janus kinase-signal transducer and activator of transcription (JAK/STAT) pathway are known to be involved in inflammatory immune-mediated skin diseases, including psoriasis. The development of drugs targeting the JAK/STAT signaling pathway...
LA  - en
PB  - Frontiers Research Foundation
KW  - JAK inhibitors
KW  - Abrocitinib
KW  - Autoimmune diseases
KW  - Deucravacitinib
KW  - Psoriasis
KW  - Ruxolitinib
KW  - Tofacitinib
KW  - Janus kinase inhibitors
KW  - Janus kinases
KW  - Deucravacitinib
KW  - Signal transduction
KW  - Psoriasis
KW  - Pharmaceutical preparations
TI  - A Scoping Review on Use of Drugs Targeting the JAK/STAT Pathway in Psoriasis.
TY  - research article
VL  - 9
ER  -